ImmunityBio
NewsRecent Press Releases
ImmunityBio Study Shows Positive T Cell and Antibody Immune Responses to its COVID-19 Vaccine Candidate that Targets Both Spike and Nucleocapsid Virus Proteins
Preclinical results show this next generation Adeno (hAd5) vaccine, which targets both spike (S) and nucleocapsid (N) SARS-CoV-2 proteins, generates CD4+ and CD8+ T-cell responses, both of which can form long-term immune memory. Inclusion of nucleocapsid in this...
ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‘Operation Warp Speed’ to Develop Novel Adenovirus COVID-19 Vaccine
ImmunityBio’s COVID-19 vaccine candidate was selected for Operation Warp Speed, a national program to accelerate COVID-19 vaccine development. Candidate is the first human adenovirus (Ad5) vaccine designed to deliver both Spike (S) and Nucleocapsid (N) DNA for...
NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference
EL SEGUNDO, Calif., May 26, 2020 – NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET. The...
NantKwest and ImmunityBio to Initiate a Phase 2 Study of Immunotherapy for Metastatic Pancreatic Cancer
Open-label, randomized Phase 2 study will evaluate combination immunotherapy, including NantKwest’s PD-L1 tumor-targeted natural killer cells and ImmunityBio’s IL-15 superagonist N-803 with standard of care versus standard of care alone Metastatic pancreatic cancer...
NantKwest and ImmunityBio to Present at the Bank of America Merrill Lynch Global Healthcare Conference
EL SEGUNDO, Calif., April 29, 2020 – NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., today announced that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the virtual Bank of America Merrill Lynch Global Healthcare Conference on May...
NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting Covid-19; Clinical Trials Anticipated to Begin This Quarter
Immunotherapy companies led by Dr. Patrick Soon-Shiong are developing potential coronavirus therapeutics and vaccines to address the evolving stages of disease from moderate infection to severe acute respiratory distress syndrome (SARS) Vaccine Vector to...
Rationale for IL-15 Superagonists in Cancer Immunotherapy
Karin M. Knudson, James W. Hodge, Jeffrey Schlom & Sofia R. Gameiro To cite this article: Karin M. Knudson, James W. Hodge, Jeffrey Schlom & Sofia R. Gameiro(2020): Rationale for IL-15 superagonists in cancer immunotherapy, Expert Opinion on BiologicalTherapy,...
ImmunityBio Combines Supercomputing Power with Microsoft Azure to Target Infection “Doorway” of the Coronavirus
Joint efforts combine a total of 24 petaflops of GPU computing power between ImmunityBio and Microsoft, enabling simulation of 200 μs per day of binding between the COVID-19 spike protein and the host ACE-2 surface protein - a crucial step to develop proteins to stop...
ImmunityBio Announces Durable Virus Control of SHIV Without Anti-Retroviral Therapy by Activating NK and Memory T Cells with N-803, an IL-15 Superagonist
ImmunityBio Announces Durable Virus Control of SHIV Without Anti-Retroviral Therapy by Activating NK and Memory T Cells with N-803, an IL-15 Superagonist First demonstration of durable control of viremia without antiviral therapy in 9 of 13 SHIV-infected monkeys...
Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference
Complete Responses Noted in Multiple Tumor Types (including Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer, Merkel Cell Cancer, Bladder Cancer, and Non-Hodgkin’s Lymphoma) when Natural Killer cells and T cells are activated simultaneously FDA...
Contact Us
© 2020 ImmunityBio, Inc. All rights reserved.